Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2015
Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials.
Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Repeatability of quantitativeEuropean journal of nuclear medicine and molecular imaging · 2018Pooled it
- Trial
- Reproducibility and Repeatability of SemiquantitativeJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Trial
- Towards real-time topical detection and characterization of FDG dose infiltration prior to PET imaging.European journal of nuclear medicine and molecular imaging · 2016Trial
- Repeatability of Quantitative 18F-NaF PET: A Multicenter Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016Trial
- A randomized, double-blind, crossover comparison of novel continuous bed motion versus traditional bed position whole-body PET/CT imaging.European journal of nuclear medicine and molecular imaging · 2016Trial
- Zero-TE MRI-based attenuation correction for bone components on chest [Annals of nuclear medicine · 2026Article
- Characterization of Pulmonary Sclerosing Pneumocytoma Assessed byThoracic cancer · 2025Article
- A machine learning model incorporatingQuantitative imaging in medicine and surgery · 2025Article
- Data-driven gated positron emission tomography/computed tomography for radiotherapy.Physics and imaging in radiation oncology · 2024Review
- Healthy tissue metabolism assessed by [Scientific reports · 2024Article
- Repeatability ofEJNMMI research · 2024Article
- Precision of quantitative parameters ofQuantitative imaging in medicine and surgery · 2023Article
- Shortened duration whole bodyEJNMMI physics · 2022Article
- New standards for phantom image quality and SUV harmonization range for multicenter oncology PET studies.Annals of nuclear medicine · 2022Article
- PET-CT for the diagnosis and treatment of primary musculoskeletal tumors in Chinese patients - experience from 255 patients in a single center.The British journal of radiology · 2021Article
- Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management.European journal of nuclear medicine and molecular imaging · 2021Review
- A convolutional neural network for fully automated blood SUV determination to facilitate SUR computation in oncological FDG-PET.European journal of nuclear medicine and molecular imaging · 2021Article
- Impact of segmentation and discretization on radiomic features inEJNMMI physics · 2021Article
- Use of population input functions for reduced scan duration whole-body PatlakEJNMMI physics · 2021Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
15 authors.
Funding
Abstract
unlabelledPET/CT with the glucose analog (18)F-FDG has several potential applications for monitoring tumor response to therapy in patients with non-small cell lung cancer (NSCLC). A prerequisite for many of these applications is detailed knowledge of the repeatability of quantitative parameters derived from (18)F-FDG PET/CT studies.
methodsThe repeatability of the (18)F-FDG signal was evaluated in 2 prospective multicenter trials. Patients with advanced NSCLC (tumor stage III-IV) underwent two (18)F-FDG PET/CT studies while not receiving therapy. Tumor (18)F-FDG uptake was quantified by measurement of the maximum standardized uptake value within a lesion (SUVmax) and the average SUV within a small volume of interest around the site of maximum uptake (SUVpeak). Analysis was performed for the lesion in the chest with the highest (18)F-FDG uptake and a size of at least 2 cm (target lesion) as well as for up to 6 additional lesions per patient. Repeatability was assessed by Bland-Altman plots and calculation of 95% repeatability coefficients (RCs) of the log-transformed SUV differences.
resultsTest-retest repeatability was assessed in 74 patients (34 from the ACRIN 6678 trial and 40 from the Merck MK-0646-008 trial). SUVpeak was 11.57 ± 7.89 g/mL for the ACRIN trial and 6.89 ± 3.02 for the Merck trial. The lower and upper RCs were -28% (95% confidence interval [CI], -35% to -23%) and +39% (95% CI, 31% to 54%) in the ACRIN trial, indicating that a decrease of SUVpeak by more than 28% or an increase by more than 39% has a probability of less than 2.5%. The corresponding RCs from the Merck trial were -35% (95% CI, -42% to -29%) and +53% (95% CI, 41% to 72%). Repeatability was similar for SUVmax of the target lesion, averaged SUVmax, and averaged SUVpeak of up to 6 lesions per patient.
conclusionThe variability of repeated measurements of tumor (18)F-FDG uptake in patients with NSCLC is somewhat larger than previously reported in smaller single-center studies but comparable to that of gastrointestinal malignancies in a previous multicenter trial. The variability of measurements supports the definitions of tumor response according to PET Response Criteria in Solid Tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.